Results 51 to 60 of about 5,281 (192)

From Mycosynthesis to Immunomodulation: Exploring the Safety, Adjuvant Potential and Microbiota Impact of Biogenic Silver Nanoparticles

Microbial Biotechnology, Volume 19, Issue 7, July 2026.
Mycosynthesized silver nanoparticles from fungal strains act as safe, biocompatible vaccine adjuvants. They enhance immune responses in mice, promoting strong, dose‐dependent IgG2a polarization with minimal toxicity and limited gut microbiota disruption, highlighting their potential as versatile next‐generation platforms for subunit vaccine development.
Ana Clara Muniz‐Lagos, Diego M. Roldán, Paula Arbildi, Gustavo Mourglia‐Ettlin, Silvana Alborés   +4 more
wiley   +1 more source

Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. [PDF]

PLoS ONE, 2011
INTRODUCTION: The propensity for influenza viruses to mutate and recombine makes them both a familiar threat and a prototype emerging infectious disease.
David N Fisman, Ashleigh R Tuite
doaj   +1 more source

The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination

, 2013
Vaccines are the most effective agents to control infections. In addition to the pathogen antigens, vaccines contain adjuvants that are used to enhance protective immune responses. However, the molecular mechanism of action of most adjuvants is ill-known,
M. Taccone, A. Seubert, Taccone M, Caccin P, FALZONI, Simonetta, DONVITO, Giovanna, Montecucco C, Palmieri E, DI VIRGILIO, Francesco, Seubert A., Gallotta M, De Gregorio E, Vono M, S. Falzoni, G. Donvito, M. Gallotta, E. Palmieri, MONTECUCCO, CESARE, Pallaoro M, M. Vono, M. Pallaoro, R. Rappuoli, CACCIN, PAOLA, F. Di Virgilio, E. De Gregorio, Rappuoli R, Seubert A, Di Virgilio F, Donvito G, Falzoni S   +29 more
core   +1 more source

Immunogenicity of High-Dose Versus MF59-Adjuvanted Versus Standard Influenza Vaccine in Solid Organ Transplant Recipients: The Swiss/Spanish Trial in Solid Organ Transplantation on Prevention of Influenza (STOP-FLU Trial) [PDF]

, 2023
BACKGROUND The immunogenicity of the standard influenza vaccine is reduced in solid-organ transplant (SOT) recipients, so that new vaccination strategies are needed in this population. METHODS Adult SOT recipients from nine transplant clinics in
Venzin, Reto M., Schuurmans, Macé, Cédric Hirzel, Munting, Aline, Golshayan, Dela, Uyen Huynh-Do, Dela Golshayan, Guido Stirnimann, Koller, Michael, Laura Walti, Huynh-Do, Uyen, Matteo Mombelli, Christoph Berger, Egli, Adrian, Jean Villard, Stirnimann, Guido, Michael Koller, Michael Dickenmann, John-David Aubert, Steiger, Jürg, Aurelia Schnyder, Swiss Transplant Cohort Study, Javier Sánchez-Céspedes, Berger, Christoph, Melanie Schönenberger, Walti, Laura Naëmi, Mombelli, Matteo, Magenta, Lorenzo, Adrian Egli, Dahdal, Suzan, Schönenberger, Melanie, Garzoni, Christian, Pascual, Manuel, Neofytos, Dionysios; https://orcid.org/, Mueller, Thomas F, Lorenzo Magenta, Manuel, Oriol, Thomas F Mueller, Susanne Stampf, Dickenmann, Michael, Aline Munting, Christian van Delden, Manuel Pascual, Walti, Laura, Isabelle Binet, Hirzel, Cédric, Egli, Adrian; https://orcid.org/, Neofytos, Dionysios, Oriol Manuel, Venzin, Reto M, Elisa Cordero, Dionysios Neofytos, Schnyder, Aurelia, Reto M Venzin, Mueller, Nicolas J., Mueller, Nicolas J, Jürg Steiger, Binet, Isabelle, Aubert, John-David, Stampf, Susanne, Villard, Jean, Christian Garzoni, Mueller, Thomas F., Macé Schuurmans, van Delden, Christian, Regli, Adrian, Sánchez-Céspedes, Javier, Cordero, Elisa, et al, Suzan Dahdal, Nicolas J Mueller, Aubert, J.D., Mueller, N.J., Venzin, R.M., Golshayan, D., Sánchez-Céspedes, J., Mombelli, M., Schuurmans, M., Koller, M., Dickenmann, M., Garzoni, C., Berger, C., Cordero, E., Villard, J., Hirzel, C., Schönenberger, M., Steiger, J., Neofytos, D., Walti, L., Dahdal, S., Magenta, L., Stirnimann, G., Stampf, S., van Delden, C., Schnyder, A., Munting, A., Egli, A., Mueller, T.F., Manuel, O., Huynh-Do, U., Binet, I., Pascual, M.   +101 more
core   +2 more sources

Immunogenicity of a Multi‐Epitope Influenza Composite Peptide Vaccine Targeting Human, Swine, and Avian Viruses: Advancing Pandemic Preparedness

Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.
ABSTRACT Background The emergence of novel reassortant influenza A virus strains and zoonotic transmission to the human population is a critical factor in the development of a global pandemic, as exemplified by the 2009 swine flu pandemic and the ongoing threat of an H5N1 avian flu pandemic.
Nimisha Rikhi, Clara J. Sei, Kellie A. Fraser, Kevin Muema, Aba Assiaw‐Dufu, Richard F. Schuman, Gerald W. Fischer   +6 more
wiley   +1 more source

Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence

Human Vaccines & Immunotherapeutics, 2019
Seasonal influenza is a very common disease. Yearly vaccination of at-risk population groups is a well-recognized cost-effective/cost-saving preventive measure.
Ilaria Loperto, Andrea Simonetti, Antonio Nardone, Maria Triassi   +3 more
doaj   +1 more source

Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children

, 2015
Mass immunization of children has the potential to decrease infection rates and prevent the transmission of influenza. We evaluated the immunogenicity, safety, and tolerability of different formulations of cell-derived MF59-adjuvanted and nonadjuvanted A/
Pedotti, Paola, Lattanzi, Maria, Rivera, Luis, Arora, Ashwani Kumar, Knuf, Markus, Rumke, Hans, Kieninger, Dorothee, Leroux-Roels, Geert, Della Cioppa, Giovanni   +8 more
core   +1 more source

Immunopotentiation by Natural Extracts: Mechanisms and Applications in Influenza Vaccine Adjuvant Development

Food Science &Nutrition, Volume 14, Issue 5, May 2026.
Natural Extracts as Candidate Influenza Vaccine Adjuvants. Seasonal influenza vaccines face limitations due to viral mutations and low efficacy in vulnerable populations. Traditional adjuvants often have safety or immune‐activation constraints, leading to increased interest in natural extracts from plants, marine organisms, and fungi.
Thi Len Ho, Eun‐Ju Ko
wiley   +1 more source

Relative efficacy and immunogenicity of the MF59 regimen.

, 2019
Unless stated otherwise, all assays, experiments and graphs associated with the MF59 study are represented by full blue circles, those of the AlumN10.8 study are represented by full green circles, and only available samples (i.e., those not depleted in ...
Melvin N. Doster (6694943), Ruth M. Ruprecht (8072033), Josh Kramer (1517812), Luca Schifanella (6694940), Celia C. LaBranche (172138), Karin Loré (8072030), Xiaoying Shen (164029), David J. Venzon (7478117), Sanjay Phogat (3780025), Frank Liang (6858878), Hung V. Trinh (5146997), Michelle Metrinko (6858884), Massimiliano Bissa (4811226), David C. Montefiori (7392644), Monica Vaccari (782730), Dallas R. Brown (6694934), Mangala Rao (147350), Galit Alter (91383), Robyn Washington-Parks (8072024), Susan W. Barnett (8072021), Georgia D. Tomaras (7163792), Matthew Breed (6858886), Namal P. M. Liyanage (8072027), Ranajit Pal (782728), William Magnanelli (6858883), Veronica Galli (6858876), Genoveffa Franchini (384425)   +26 more
core   +1 more source

Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children

Journal of Infection in Developing Countries, 2014
Introduction: The efficacy of non-adjuvanted seasonal influenza vaccine in young children is considered to be suboptimal.  This study compared the safety and immunogenicity profiles of MF59-adjuvanted, trivalent, influenza vaccine (ATIV) and non ...
Adib Rodriguez Solares, Carlos Grazioso Aragon, Rodolfo Urruela Pivaral, David Prado-Cohrs, Victor Sales-Carmona, Michele Pellegrini, Nicola Groth   +6 more
doaj   +1 more source